Active site-inactivated factor VIIa has potential as an antithrombotic agent. The effects of D-Phe-L-Phe-L-Arg-chloromethyl ketone-treated factor VIla (FFR-FVIIa) were evaluated in a cell-based system mimicking in vivo initiation of coagulation. FFR-FVIIa inhibited platelet activation (as measured by expression of P-selectin) and subsequent large-scale thrombin generation in a dose-dependent manner with IC50 values of 1.4 ± 0.8 nM (n = 8) and 0.9 ± 0.7 nM (n = 7), respectively. Kd for factor VIIa binding to monocytes ki for FFR-FVIIa competing with factor VIIa were similar (11.4 ± 0.8 pM and 10.6 ± 1.1 pM, respectively), showing that FFR-FVIIa binds to tissue factor in the tenase complex with the same affinity as factor VIIa. Using platelets from volunteers before and after ingestion of aspirin (1.3 g), there were no significant differences in the IC50 values of FFR-FVIIa [after aspirin ingestion, the IC50 values were 1.7 ± 0.9 nM (n = 8) for P-selectin expression, p = 0.37, and 1.4 ± 1.3 nM (n = 7) for thrombin generation, p = 0.38]. This shows that aspirin treatment of platelets does not influence the inhibition of tissue factor-initiated coagulation by FFR-FVIIa, probably because thrombin activation of platelets is not entirely dependent upon expression of thromboxane A2.
References
1
Camerer E,
Kolstø A-B,
Prydz H.
Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 01-41
4
Fleck RA,
Rao LVM,
Rapaport SI,
Varski N.
Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal antihuman tissue factor antibody. Thromb Res 1990; 59: 421-437
5
Flössel C,
Luther T,
Muller M,
Albrecht S,
Kasper M.
Immunohistochemical detection of tissue factor (TF) on paraffin sections of routinely fixed human tissue. Histochemistry 1994; 101: 449-453
6
Wilcox JN,
Smith KM,
Schwartz SM,
Gorden D.
Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843
8
Sørensen BB,
Persson E,
Freskgård P-O,
Kjalke M,
Ezban M,
Williams T,
Rao LVM.
Incorporation of an active site inhibitor in factor Vila alters the affinity for tissue factor. J Biol Chem 1997; 272: 11863-11868
9
Ørvim U,
Barstad RM,
Öming L,
Petersen LB,
Ezban M,
Hedner U,
Sakariassen KS.
Inactive active site recombinant FVIIa is an efficient inhibitor of tissue factor FVIIa induced arterial thrombus formation in human blood. Thromb Haemost 1995; 73: 1185
10
Kirchhofer D,
Tschopp TB,
Baumgartner HR.
Active site-blocked factors Vila and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler Thromb Vase Biol 1995; 15: 1098-1106
13
Jang Y,
Guzman LA,
Lincoff AM,
Gottsauner-Wolf M,
Forudi F,
Hart CE,
Courtman DW,
Ezban M,
Ellis SG,
Topol EJ.
Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit arthero-sclerotic femoral artery injury model. Circulation 1995; 92: 3041-3050
14
Amljots B,
Ezban M,
Hedner U.
Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor Vila. J Vase Surg 1997; 25: 341-346
17
Takahara K,
Murray R,
Fitzgerald GA,
Fitzgerald DJ.
The response to thromboxane A2analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem 1990; 265: 6836-6844
20
Bjomsson TD,
Schneider DE,
Berger JR H.
Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989; 250: 154-161
23
Hoffman M,
Monroe DM,
Oliver JA,
Roberts HR.
Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 1995; 86: 1794-1801
24
Church FC,
Meade JB,
Treanor RE,
Whinna HC.
Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. J Biol Chem 1989; 264: 3618-3623
26
Thim L,
Bjoem S,
Christensen M,
Nicolaisen EM,
Lund-Hansen T,
Pedersen AH,
Hedner U.
Amino acid sequence and posttranslational modifications of human factor Vila from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 7785-7793
27
Weiss HJ,
Lages B.
Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 71: 629-635
28
Oliver JA,
Hoffman M,
Monroe DM,
Ezban M,
Hedner U,
Roberts HR.
Active site-inhibited coagulation factor Vila blocks platelet activation, thrombin generation, and accumulation of platelet-bound factor X in a tissue factor-initiated system. Blood 1995; 86 (Suppl. 01) 77a
29
Monroe DM,
Hoffman M,
Roberts HR.
Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coag Fibrinol 1996; 7: 459-464
31
Kaiser B,
Koza M,
Walenga JM,
Fareed J.
Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb Res 1996; 82: 257-263
32
Sabharwal AK,
Birktoft JJ,
Gorka J,
Wildgoose P,
Petersen LC,
Bajaj SP.
High affinity Ca2+-binding site in the serine protease domain of human factor Vila and its role in tissue factor binding and development of catalytic activity. J Biol Chem 1995; 270: 15523-15530
36
Ruf W,
Kalnik MW,
Lund-Hansen T,
Edgington T.
Characterization of factor VII association with tissue factor in solution. High and low affinity calcium binding sites in factor VII contribute to functionally distinct interactions. J Biol Chem 1991; 266: 15719-15725
37
Ruf W,
Miles DJ,
Rehemtulla A,
Edgington TS.
Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor Vila protease complex. J Biol Chem 1992; 267: 6375-6381
38
Chang GTG,
Kisiel W.
Internalization and degradation of recombinant human coagulation factor Vila by the human hepatoma cell line HuH7. Thromb Haemost 1995; 73: 231-238
39
Sakai T,
Lund-Hansen T,
Paborsky L,
Pedersen AH,
Kisiel W.
Binding of human factors VII and Vila to human bladder carcinoma cell line (J82). Implications for the initiation of the extdnsix pathway of blood coagulation. J Biol Chem 1989; 264: 9980-9988
40
Nemerson Y,
Gentry R.
An ordered addition, essential activation model of the tissue factor pathway of coagulation: Evidence for a conformational cage. Biochemistry 1986; 25: 4020-4033
44
Mielke CH,
Kaneshiro MM,
Maher IA,
Weiner JM,
Rapaport SI.
The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204-215
45
Fiore LD,
Brophy MT,
Lopez A,
Janson P,
Deykin D.
The bleeding time response to aspirin. Identifying the hyperresponder. Am J Clin Pathol 1990; 94: 292-296
47
Young VP,
Giles AR,
Pater J,
Corbett WEN.
Sex differences in bleeding time and blood loss in normal subjects following aspirin administration. Thromb Res 1980; 20: 705-709
48
Holmsen H.
Platelet secretion and energy metabolism. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, third edition.
Colman RW,
Hirsh J,
Marder VJ,
Salzman EW.
J. B. Lippincott Company; Philadelphia: 1994. pp 524-545
49
Rand ML,
Perry DW,
Packham MA,
Gemmell CH,
Yeo EL,
Kinlough-Rathbone RL.
Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: Direct measurements of percent release of P-thromboglobulin and assessment by flow cytrometry of P- selectin expression. Am J Hematol 1996; 52: 288-294
50
Chronos NAF,
Wilson DJ,
Janes SL,
Hutton RA,
Buller NP,
Goodall AH.
Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of α-granules or lysosomes from, human platelets. Clin Sci 1994; 87: 575-580
54
Prager NA,
Torr-Brown SR,
Sobel BE,
Abendschein DR.
Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Coll Cardiol 1993; 22: 296-301
